Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007)

Abstract

BACKGROUND This study was designed to determine the feasibility, maximum tolerated dose, and toxicities of intraarterial administration of paclitaxel‐albumin nanoparticles in patients with advanced head and neck and recurrent anal canal squamous cell carcinoma. Antitumor activity also was assessed. METHODS Forty‐three patients (31 with advanced head and neck and 12 with recurrent anal canal squamous cell carcinoma) were treated intraarterially with ABI‐007 every 4 weeks for 3 cycles. In total, 120 treatment cycles were completed, 86 in patients with head and neck carcinoma (median, 3 cycles; range, 1–4) and 34 in patients with anal canal carcinoma (median, 3 cycles; range, 1–4). ABI‐007 was compared preliminarily with Taxol® for in vitro cytostatic activity. Increasing dose levels from 120 to 300 mg/m2 were studied in 18 patients. Pharmacokinetic profiles after intraarterial administration were obtained in a restricted number of patients. RESULTS The dose‐limiting toxicity of ABI‐007 was myelosuppression consisting of Grade 4 neutropenia in 3 patients. Nonhematologic toxicities included total alopecia (30 patients), gastrointestinal toxicity (3 patients, Grade 2), skin toxicity (5 patients, Grade 2), neurologic toxicity (4 patients, Grade 2) ocular toxicity (1 patient, Grade 2), flu‐like syndrome (7 patients, Grade 2; 1 patient, Grade 3). In total, 120 transfemoral, percutaneous catheterization procedure–related complications occurred only during catheterization of the neck vessels in 3 patients (2 TIA, 1 hemiparesis) and resolved spontaneously. CONCLUSIONS Intraarterial administration of ABI‐007 by percutaneous catheterization does not require premedication, is easy and reproducible, and has acceptable toxicity. The maximum tolerated dose in a single administration was 270 mg/m2. Most dose levels showed considerable antitumor activity (42 assessable patients with 80.9% complete response and partial response). The recommended Phase II dose is 230 mg/m2 every 3 weeks. Cancer 2001;92:2592–602. © 2001 American Cancer Society.

Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer

“…Progress in the field of cancer nanomedicine is evident from the entry of several NP-based therapies and an increasing number of ongoing clinical studies for treating different types of cancers [34, 35]. In general, the efficacy of NPs has been attributed to either better drug delivery directly to cancerous tissue and/or reduced toxicity compared with drugs alone.…”

TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer

“…PXL induces apoptosis by over-stabilizing microtubules (7), which leads to cell arrest at the G2/M phase (8). Although the therapeutic utility of PXL has been improved by formulating it as nanoparticles(nab-PXL) (9), the overall response of breast cancer (BC) patient seven to this advanced therapy remains below 35% (10). The main reason for low response rate is tumor recurrence after cessation of therapy, which might relate to PXL-mediated induction of inflammatory mediators including TNF-α (11), IL-1β(12), IL-8(13), IL-6 (14)and VEGF-A (3, 4).…”

Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach

“…However, recent evidence has shown that PEG, which was previously considered to be biologically inert, could still induce certain adverse effects through activation of the complement system [14]. Other approaches using polymer-based or organic nanoparticles (Abraxan®) are used clinically, but these are limited by the lack of controlled drug release at specific sites due to longevity in the blood stream, which leads to adverse effects [15].…”